STAT+: Teladoc’s earnings point to potential threats to the telehealth industry
Telehealth giant Teladoc is bracing for disappointing earnings this year as it faces headwinds that…
Category: STAT+
STAT+: Pharmalittle: AbbVie’s Allergan reaches $2 billion deal on opioid lawsuits; internal IQVIA documents question patient data privacy
Rise and shine, folks. Another busy day is upon us. And it looks to be…
STAT+: Top IQVIA lawyer declines to discuss Experian relationship, but pledges Americans’ medical secrets are safe
For years, the health data company IQVIA has quietly purchased detailed financial and demographic information…
Opinion: STAT+: How to close biopharma’s data science and engineering skills gap
In biopharma research and development, laboratory data now exist in petabytes. Today’s fastest liquid-handling robots…
STAT+: Internal documents on IQVIA’s secretive relationship with Experian undercut its image as a Fort Knox of patient data
To the outside world and its countless health care customers, the data powerhouse IQVIA has…
STAT+: AbbVie is scolded by a trade group over sales rep ‘strategically loitering’ in a hospital
In an embarrassing episode for AbbVie, the company was reprimanded by a U.K. pharmaceutical industry…
STAT+: Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices
In his ongoing quest to probe pharmaceutical industry tax practices, the head of the U.S….
STAT+: Pharmalittle: Teva reaches $4.25 billion deal over its role in opioid crisis; feds probe Cassava over Alzheimer’s drug data
Top of the morning to you. Another deliciously shiny day is unfolding over the Pharmalot…
STAT+: Genomics is racing toward a $100 genome. Are we ready for it?
As the cost of DNA sequencing plummets, we’re fast approaching a point when decoding a…
STAT+: FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street
Once again, the U.S. Food and Drug Administration made a surprise move regarding an experimental…
STAT+: Pharmalittle: FDA will review Biogen ALS drug despite inconclusive results; Shkreli launches drug-discovery software company
Rise and shine. Another busy day is on the way. Indeed, the official to-do list…
STAT+: FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results
The Food and Drug Administration has agreed to review a treatment for a rare, genetically…
STAT+: ‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing
WASHINGTON — The pharmaceutical industry, notorious for its deep pockets and aggressive lobbying tactics, has a…
STAT+: American Cancer Society’s VC arm partners with Third Rock on oncology companies
Cancer startups aren’t exactly underfunded — as a disease area, oncology has commanded investors’ attention…
STAT+: Despite their anger over high drug prices, Americans are giving pharma credit for helping contain Covid-19
WASHINGTON – Nearly three quarters of Americans give the pharmaceutical industry credit for helping contain…
STAT+: ‘No magic bullet’: For drugmakers and the FDA, clinical trials on ultra-rare diseases pose thorny challenges
Walker Burger is beside himself with worry. The 33-year-old relies on an experimental medicine to…
STAT+: McDonald’s is criticized for leaving antibiotic reduction targets off its menu
Several advocacy groups have a beef with McDonald’s over its policy for using antibiotics in…
STAT+: Pfizer loses another court battle alleging the U.S. illegally limits use of copay assistance programs
In another setback for the pharmaceutical industry, a federal appeals court panel upheld a ruling…
STAT+: Pharmalittle: White House to launch effort for new generation of Covid shots; Indian court rejects bail pleas in Biocon bribery case
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: A troubling report on Cerner’s VA rollout offers a rare look into the hidden harms of health records
The rollout of Cerner’s electronic health record in Veterans Affairs hospitals has been a high-profile…
STAT+: Four brain-computer interface companies you should watch (other than Neuralink)
The term “brain-computer interface,” or BCI, has been buzzing around Silicon Valley and the mainstream…
STAT+: Amazon has big ambitions in primary care. One Medical is just the latest piece of its plan
When it comes to primary care, One Medical is hardly Amazon’s first rodeo. By the…
STAT+: Pharmalittle: Congress may miss deadline to pass FDA user-fee bill; ViiV is urged to lower price for its HIV prevention drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: 5 burning questions about Amazon’s $3.9 billion acquisition of One Medical
With its acquisition of One Medical, Amazon is setting its sights squarely on shaking up…
STAT+: Serving as a ‘clinical colleague,’ AI shows potential to reduce sepsis deaths in real-world studies
Three studies published Thursday found that an AI platform developed by Bayesian Health and Johns…
STAT+: Pharmalittle: Roche CEO to step down next year; Gates Foundation withdraws financial support for malaria vaccine
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Amazon to acquire One Medical for $3.9 billion in a bold bet on primary care
Retail giant Amazon announced plans Thurday to acquire primary care company One Medical in a…
.jpg)
STAT+: Researchers tried to calculate the impact of health tech companies. It sent startups into a tizzy
As Johns Hopkins gastroenterologist Simon Mathews has watched scores of digital health upstarts collect hundreds…
STAT+: As health care faces nursing shortages, burned-out nurses are flocking to remote jobs
Burned out and fed up with their work conditions, nurses are leaving the bedside in…
STAT+: Biogen agrees to pay $900 million to settle whistleblower case alleging kickbacks and sham speaking events
After a decade of legal squabbling, Biogen has agreed in principle to pay $900 million…
STAT+: Pharmalittle: Pharma and advocacy groups differ on vaccine equity; EC says Illumina-Grail deal breached merger rules
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
Opinion: STAT+: 10 tips for vendors seeking to create or expand digital health and virtual health solutions
Virtual and digital care expanded dramatically during the pandemic as patients, providers, employers, and regulators…
STAT+: Medicare offers financial perks for rural hospitals that convert to its new provider type. Will they bite?
The federal government is hashing out the details on a new type of rural hospital,…
STAT+: Pharma and advocacy groups offer competing visions for achieving vaccine equity during pandemics
Amid criticism over its approach to Covid-19, the pharmaceutical industry has issued a new “declaration”…
STAT+: Pharmalittle: FDA user-fee reauthorization bill hits a snag; USPTO takes a tougher stand toward drugmakers
Rise and shine. Another busy day is on the way. Indeed, the official to-do list…
STAT+: The politics of passing a major FDA funding bill just got complicated
WASHINGTON — For the last six months, Congress seemed to be sailing towards the uncharacteristically…
STAT+: This biotech is betting dietary changes can reshape cancer care. Even if it works, can Faeth make a profit?
For all the advances oncology researchers have made in genomics and precision medicine, one of…
STAT+: Dozens of lawmakers urge HHS to fine drugmakers for curtailing discounts to a federal program
Dozens of lawmakers are demanding the Biden administration penalize drug companies that have curtailed discounts…
STAT+: Federal patent initiatives could cause ‘headwinds’ for drugmakers and their broad filings
For the second time this month, the U.S. Patent & Trademark Office has taken a…
STAT+: Contract research organization to transfer 4,000 beagles from facility cited for inhumane care
A contract research organization reached a final settlement with the U.S. government to transfer about…
STAT+: Pharmalittle: Biotech CEOs pull in some of health care’s biggest paydays; split emerges between groups providing abortion pills
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: UnitedHealth Group says Medicare Advantage saves money, but the data say otherwise
This past June, UnitedHealth Group’s top two executives, Andrew Witty and John Rex, told a…
Opinion: STAT+: For safety’s sake, it’s time to get medical device identifiers over the finish line
This week, an under-the-radar U.S. government advisory group called the National Committee on Vital and…
STAT+: New data might have led to a different result for Amarin fish oil drug, FDA panelists say
Two members of an expert panel that recommended the Food and Drug Administration approve a…
STAT+: Edwards Lifesciences chief tops list of highest-paid medical device CEOs
Medical device executives generally made less in 2021 than in 2020, as the pandemic again…
STAT+: HCA Healthcare, Cigna chiefs top the lists of best-paid CEOs among providers, insurers
Health insurers and providers often argue over payments at the negotiating table, but in the…
STAT+: The pandemic brought an influx of cash for health tech companies — and huge payouts for their execs
The pandemic brought a windfall for private health tech startups and fueled a rush to…
STAT+: Biotech executives pull in some of health care’s biggest paydays, with Regeneron’s CEO sitting atop the pack
When it comes to executive compensation in the biotech and pharma sectors, it pays to…
STAT+: UnitedHealthcare to offer $0 insulin, Epi-Pens, but only for some members
Next year, UnitedHealthcare will offer employer health plans that have no copays or out-of-pocket costs…
STAT+: Pharmalittle: Will the Supreme Court review controversial patent rulings? GSK prepares for its consumer health spinoff
And so, another working week will soon draw to a close. Not a moment too…